KSQ Therapeutics Competitors, Revenue and Alternatives
Estimated Revenue & Financials
- KSQ Therapeutics's estimated annual revenue is currently $11.5M per year.
- KSQ Therapeutics received $80.0M in venture funding in October 2018.
- KSQ Therapeutics's estimated revenue per employee is $201,000
- KSQ Therapeutics's total funding is $156.6M.
- KSQ Therapeutics has 57 Employees.
- KSQ Therapeutics grew their employee count by -38% last year.
- KSQ Therapeutics currently has 1 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Vita Data Scien...||$10.3M||51||50%||N/A|
What Is KSQ Therapeutics?
KSQ Therapeutics has built an industry-leading genome-scale precision functional genomics platform, called CRISPRomics, to pinpoint therapeutic nodes that directly correlate genomic function to disease with unprecedented certainty and speed. The company is deploying CRISPRomics for novel drug development across broad therapeutic areas and is currently advancing a proprietary pipeline of tumor- and immune-focused drug candidates. KSQ was founded by thought leaders in the field of functional genomics and pioneers of CRISPR screening technologies, and the company is located in Cambridge, Massachusetts. For more information, please visit the company's website at www.ksqtx.com.keywords:N/A
Number of Employees
Employee Growth %
|Jason Merkin||Principal Scientist|
|Caroline Dugopolski||VP, Head of Technical Operations|
|Jeff Davis||Head Of Clinical Operations||Email Available|
|Beni Wolf||Chief Medical Officer||Email Available|
|John Cho||Principal Scientist|
|Gregory Kryukov||Sr. Director, Computational Biology||Email Available|
|Giovanni Cianchetta||Director Computational Chemistry||Email Available|
|Rene Lemieux||Vice President, Head Of Small Molecule Drug Discovery|
|Andrew Olaharski||Senior Director And Head Of Toxicology||Email Available|
|Louise Cadzow||Senior director, head of in vivo||Email Available|
KSQ Therapeutics News
... (AVIR); Denali Therapeutics (DNLI); Rubius Therapeutics (RUBY); Syros Pharmaceuticals (SYRS); Sana Biotechnology; KSQ Therapeutics; ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- KSQ Therapeutics today announced the appointment of Douglas Pagán as Chief Financial Officer.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--KSQ Therapeutics today announced the appointment of Beni B. Wolf, MD, PhD, as Chief Medical ...
KSQ Therapeutics Funding